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Abstract
Conversion of cortisone to cortisol by 11b-hydroxysteroid de-
hydrogenase type 1 (11bHSD1) in the endoplasmic reticulum
(ER) of the target cells is a major determinant of glucocorti-
coid action, and plays an important role in the development of
obesity-related diseases. Inhibition of 11bHSD1 activity is,
therefore, considered as a promising novel strategy for the
treatment of metabolic syndrome and diabetes. Tea flavanols
and their major representative, epigallocatechin gallate are
known as antiobesity and antidiabetic agents. Their impacts
on blood glucose level, hepatic glucose production, and insu-
lin responsiveness resemble those observed on inhibition or
depletion of 11bHSD1. We aimed to study the effect of epigal-
locatechin gallate on 11bHSD1 activity in ER-derived rat liver
microsomes by measuring cortisone and cortisol with HPLC.
Cortisol production was efficiently suppressed in a concentra-
tion dependent manner in intact microsomal vesicles.
However, this effect was abolished by membrane permeabili-
zation; and the three proteins involved in the overall process
(11bHSD1, hexose 6-phosphate dehydrogenase, and glucose
6-phosphate transporter) were not or only mildly affected. Fur-
ther investigation revealed the oxidation of luminal NADPH to
NADP1, which attenuates cortisone reduction and favors corti-
sol oxidation in this compartment. Such a redox shift in the
ER lumen might contribute to the beneficial health effects of
tea flavanols and should be regarded as a promising strategy
for the development of novel selective 11bHSD1 inhibitors to
treat obesity-related diseases. VC 2013 BioFactors, 00(00):000–
000, 2013
Keywords: 11b-hydroxysteroid dehydrogenase type 1; endoplasmic
reticulum; redox shift; selective inhibitor; (–)-epigallocatechin-3-gallate;
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1. Introduction
Glucocorticoid hormones regulate the expression of several key
enzymes of the intermediary metabolism and hence play a cen-
tral role in the long-term control of fuel homeostasis [1]. Cortisol
aids the mobilization of energy sources and maintenance of
blood glucose level, which are essential for the adaptation to
physical and emotional stress, including prolonged starvation
[2]. Glucose producing capacity of the liver is largely affected by
cortisol, which stimulates the gene expression of phosphoenol-
pyruvate carboxykinase (PEPCK) and glucose 6-phosphatase
(G6Pase), two rate-limiting enzymes of hepatic gluconeogenesis
[3]. The circulating cortisol levels are adjusted to the nutrient
supply and energy demands by the hypothalamic–pituitary–ad-
renal axis. Insufficient cortisol production leads to enhanced
stress sensitivity, while cortisol overproduction causes Cushing
zczc syndrome, a complex metabolic disorder involving visceral
obesity, dyslipidemia, hypertension, insulin resistance, hyper-
glycemia, and an increased risk of type 2 diabetes [4].
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It has become evident in the last decade that, besides cir-
culating cortisol levels, prereceptor glucocorticoid activation in
the target tissues is a major determinant of the cortisol effect.
Moreover, local cortisol production was also shown to play a
central role in preadipocyte differentiation [5]. Conversion of
the prohormone, cortisone to cortisol is catalyzed by 11b-
hydroxysteroid dehydrogenase type 1 (11bHSD1) in the lumen
of the endoplasmic reticulum (ER) [6,7]. NADPH requirement
of the reaction is met by the activity of hexose 6-phosphate de-
hydrogenase (H6PD) [8], which is not only functionally coupled
but also physically associated to 11bHSD1. H6PD uses glucose
6-phosphate (G6P), which enters the ER lumen through glu-
cose 6-phosphate translocase (G6PT) [9].
The metabolic syndrome, one of the fastest growing obe-
sity-related diseases, shares the above-described symptoms of
the Cushing zczc syndrome despite the absence of elevated cir-
culating glucocorticoid levels [10]. Therefore, the role of
enhanced prereceptor cortisol production by the G6PT-H6PD-
11bHSD1 triad has been implicated in the pathomechanism of
obesity-related metabolic diseases [11]. This theory is strongly
supported by the studies using transgenic and knockout ani-
mals. Overexpression of 11bHSD1 in adipose tissue reproduces
the metabolic syndrome in mice [12], while hepatic overex-
pression leads to similar metabolic abnormalities without obe-
sity [13]. Both H6PD [14,15] and 11bHSD1 [16,17] knockout
mice display fasting hypoglycemia, improved lipid and lipopro-
tein profile, insulin sensitivity, and glucose tolerance. They
were also found to resist hyperglycemia provoked by obesity
or stress, due to attenuated gluconeogenic responses [14,16].
Inhibition of 11bHSD1 activity is, therefore, considered as a
promising novel strategy for the treatment of metabolic syn-
drome and diabetes [18].
Green tea consumption has several beneficial health
effects, which attracted a remarkable scientific attention in the
past decades [19]. Most of these observed protective and cura-
tive activities are attributed to polyphenolic molecules, which
have long been considered as semiessential food components.
Polyphenols represent 30% of the dry matter of green tea leaf,
and these polyphenols are mostly flavanol (catechin) mono-
mers, dominantly epigallocatechin, epicatechin, and their gal-
lic esters [20].
Epigallocatechin gallate (EGCG) is the most widely studied
tea flavanol. Its antiobesity and antidiabetic effects have been
demonstrated in several studies (for a review see ref. 21).
EGCG decreases body weight and fat mass [22], and it is pre-
ventive against the metabolic syndrome [23]. It was also shown
to decrease hepatic glucose production by downregulating
PEPCK and G6Pase at transcriptional level in vivo [24]. These
findings suggest that EGCG might interfere with the activity of
the G6PT-H6PD-11bHSD1 triad in the liver cells. Therefore,
the aim of this study was to reveal any possible direct effects
of EGCG on the cortisol producing machinery in the hepatic ER
by using rat liver microsomes. The results support our hypoth-
esis that decreased prereceptor glucocorticoid activation may
contribute to the antiobesity and antidiabetic effects of EGCG
and highlight the role of ER luminal NADP-NADPH pool as a
potential drug target in these pathological conditions.
2. Materials and Methods
2.1. Materials
Alamethicin, cortisone, cortisol, EGCG, G6P, metyrapone,
NADPþ, NADPH, and 4-morpholinepropanesulfonic acid
(MOPS) were purchased from Sigma Chemical (St. Louis, MO).
All other reagents and solvents were of analytical grade.
2.2. Preparation of Rat Liver Microsomes
Rat liver microsomes were prepared from male Wistar rats
(200–250 g body weights) using fractional centrifugation [25].
Microsomes resuspended in MOPS-KCl buffer (100 mM KCl, 20
mM NaCl, 1 mM MgCl2, and 20 mM MOPS, pH 7.2) were rap-
idly frozen and stored in liquid N2 until used. Intactness of
microsomal vesicles was checked by measuring the latency of
mannose 6-phosphatase activity [26], which was greater than
92% in all the preparations used. Protein concentration of the
microsomes was determined with Bio-Rad protein assay solu-
tion using bovine serum albumin as a standard according to
the manufacturer zczc instructions.
2.3. Microsomal Cortisone–Cortisol Conversion
G6P-driven reduction of cortisone to cortisol was measured by
incubating intact microsomes (0.5 mg/mL protein concentra-
tion) in MOPS-KCl buffer with 5 lM cortisone and 50 lM G6P
in the final volume of 150 lL at 37C for 30 min. The reaction
catalyzed by 11bHSD1 was assessed directly in similar condi-
tions by measuring NADPþ-driven cortisol oxidation after pre-
treatment of the microsomes with pore-forming alamethicin
(0.1 mg/mg protein). These permeabilized vesicles (0.5 mg/mL
protein) were incubated in MOPS-KCl buffer containing 5 lM
cortisol and 50 lM NADPþ in the final volume of 150 lL at
37C for 30 min. In either case, the reaction was terminated
with 150 lL ice-cold methanol, and the samples were stored at
20C until HPLC analysis of cortisone and cortisol contents.
2.4. Fluorimetric Detection of NADPH; Measurement
of H6PD and 11bHSD1 Activities
NADPH was detected by fluorimetry at 350 nm excitation and
500 nm emission wavelengths using a Cary Eclipse spectro-
fluorimeter (Varian, Woburn, MA). Endogenous NADPH con-
tent of intact microsomes was monitored at 1 mg/mL protein
concentration in MOPS-KCl buffer. Oxidation and reduction of
the luminal pyridine nucleotide pool was induced by metyra-
pone (5 lM) and G6P (100 lM), respectively. H6PD activity was
assessed by real-time detection of NADPH production. Intact
microsomes (1 mg/mL protein) were incubated in a fluorimet-
ric cuvette in MOPS-KCl buffer containing 2 mM NADPþ and
100 lM G6P at 37C to record a baseline. The reaction was
initiated by eliminating the membrane barrier using alamethi-
cin (0.1 mg/mg protein) to allow free access of the substrates
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to the intraluminal enzyme. 11bHSD1 activity was measured
similarly but G6P was replaced with cortisol (100 lM) in the
incubation medium. Fluorimetric detections were finished with
NADPH standard (0.5 lM) addition in both cases.
2.5. Endogenous Reducing/Oxidizing Capacity of the
Microsomal Vesicles
Intrinsic cortisone reducing or cortisol oxidizing capacity of
the microsomes was analyzed by incubating intact microsomal
vesicles (0.5 mg/mL protein concentration) in MOPS-KCl buffer
at 37C for 2 h in the presence of 10 lM cortisone or cortisol,
respectively. The reactions were terminated by adding equal
volume of ice-cold methanol. Samples were stored at 20C
until HPLC analysis of cortisone and cortisol contents.
2.6. HPLC Analysis
The methanol-treated samples were centrifuged (20,000g for
10 min at 4C) and the protein-free supernatants were ana-
lyzed to measure cortisone and cortisol simultaneously. Com-
pounds were separated by HPLC (Alliance 2690; Waters, Mil-
ford, MA) in a Nucleosil 100 C18 column (5 lm, 25  0.46)
(Teknokroma, Barcelona, Spain) with isocratic methanol-water
(58:42, vol/vol) at 0.7 mL/min flow rate; and the absorbance in
the eluate was detected at 245 nm wavelength (Waters Dual k
Absorbance Detector 2487). Retention times of cortisone and
cortisol were determined by injecting 10 lM standards.
2.7. Lipid Peroxidation
Oxidative damage of the membrane lipids was tested by meas-
uring the formation of thiobarbituric acid reactive substances
(TBARS). Microsomal vesicles (1 mg protein/mL) were incu-
bated in MOPS-KCl buffer for 5 min at 37C, in the absence or
presence (50 or 100 lM) of EGCG. Lipid peroxidation was trig-
gered by the combination of 100 lM Fe2þ and 1 mM ascorbate
as a positive control. TBARS were detected in samples pre-
pared by the addition of trichloroacetic acid (5% final concen-
tration) as described earlier [27].
2.8. Statistical Analysis
Experiments were performed in triplicate, with each of the
values of a single set of experiments corresponding to the
mean of a minimum of two to three determinations. Data are
presented as mean 6 SEM. The results were analyzed by one-
way ANOVA and Tukey-Kramer Multiple Comparison Test
using GraphPad PrismVR software. A P value below 0.05 was
considered as a significant difference.
3. Results
3.1. Concentration-Dependent Inhibition of
Microsomal Cortisol Production by EGCG
The possible interference of EGCG with the overall activity of
the G6PT-H6PD-11bHSD1 triad (i.e., the cortisone reducing
machinery of the ER) was tested first. Intact rat liver microso-
mal vesicles (0.5 mg/mL) were incubated in the presence of
cortisone (5 lM) and G6P (50 lM) substrates for 30 min, and
the amount of cortisol was measured with HPLC. Cortisol pro-
duction was significantly inhibited by EGCG at 25 lM level;
and the effect increased in a concentration-dependent manner
(Fig. F11). The rate of cortisone–cortisol conversion was less
than half of the control value at 25 lM and hardly detectable
above 50 lM concentrations of the flavanol.
3.2. Effect of EGCG on 11bHSD1 and H6PD Activities
Separately
Hindrance of G6P-driven cortisol production observed in intact
microsomes can be due to either direct inhibition of 11bHSD1
or decreased luminal NADPH generation. In other words, all
the three members of the G6PT-H6PD-11bHSD1 triad are
potential targets of EGCG action. However, attenuation of G6P
uptake into rat liver microsomal vesicles, that is, inhibition of
G6PT by EGCG was ruled out in our previous study [28] but
the two luminal dehydrogenases remain to be investigated.
The pore forming alamethicin (0.1 mg/mg protein) uncouples
H6PD and 11bHSD1 activities by providing free access of the
enzymes to NADP(H) cofactors added into the incubation me-
dium. Therefore, the two enzymes can be separately studied in
permeabilized microsomes.
H6PD and 11bHSD1 activities were assessed by incubation
of rat liver microsomes in the presence of NADPþ and real-
time fluorescent detection of G6P-dependent (Fig. F22) or corti-
sol-dependent (Fig. F33) NADPH production, respectively. Both
enzyme activities proved to be completely latent, that is, they
only started upon membrane permeabilization due to luminal
Microsomal cortisol production. Intact rat liver micro-
somal vesicles (0.5 mg/mL) were incubated at 37 C
for 30 min in MOPS-KCl buffer supplemented with
cortisone (5 lM), glucose 6-phosphate (50 lM), and
EGCG in different concentrations as indicated. The
amount of cortisol was then measured with HPLC.
The rate of cortisol production was calculated and
shown as mean þ SEM, n ¼ 3, **P < 0.01 versus
control.
FIG 1
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localization of the enzymes and impermeability of the ER
membrane to pyridine nucleotides. This also approves mem-
brane integrity and excludes the interference of extravesicular
activities with our measurements. The linear increment of the
fluorescent signal corresponds to H6PD or 11bHSD1-mediated
NADPH generation. H6PD activity (Fig. 2) was not affected by
EGCG even at 100 lM concentration of the flavanol (5.76 6
0.65 nmol/mg vs. 5.77 6 0.41 nmol/mg control value, mean 6
SEM; n ¼ 3); whereas 11bHSD1 activity was only slightly inhib-
ited (0.68 6 0.05 nmol/mg vs. 0.82 6 0.03 nmol/mg control
value, mean 6 SEM; n ¼ 3; P < 0.05). This effect of EGCG on
11bHSD1 activity was also tested by HPLC measurement of
cortisol–cortisone conversion in permeabilized microsomes
(Fig. F44). In line with the fluorimetric experiments, the
Hexose 6-phosphate dehydrogenase activity. Intact
microsomes (1 mg/mL protein) were incubated in a
fluorimetric cuvette in MOPS-KCl buffer containing 2
mM NADPþ and 100 lM G6P at 37 C in the absence
(top panel) or presence of 100 lM EGCG (bottom
panel). The baseline fluorescence of NADPH was
recorded at 350-nm excitation and 500-nm emission
wavelengths. H6PD activity was initiated by permea-
bilizing the membranes with alamethicin (0.1 mg/mg
protein) and the reaction was assessed by real-time
detection of NADPH production. Detections were fin-
ished with the addition of NADPH standard (0.5 lM).
Typical traces of three independent experiments are
shown.
11b-Hydroxysteroid dehydrogenase type 1 activity.
Intact microsomes (1 mg/mL protein) were incubated
in a fluorimetric cuvette in MOPS-KCl buffer contain-
ing 2 mM NADPþ and 100 lM cortisol at 37 C in the
absence (top panel) or presence of 100 lM EGCG
(bottom panel). The baseline fluorescence of NADPH
was recorded at 350-nm excitation and 500-nm emis-
sion wavelengths. 11bHSD1 activity was initiated by
permeabilizing the membranes with alamethicin (0.1
mg/mg protein) and the reaction was assessed by
real-time detection of NADPH production. Detections
were finished with the addition of NADPH standard
(0.5 lM). Typical traces of three independent experi-
ments are shown.
FIG 2
FIG 3
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alternative approach also revealed only a small inhibition.
Statistically significant, 30% reduction of 11bHSD1 activity
was found only at the highest (100 lM) EGCG concentration
(0.34 6 0.02 nmol/mg vs. 0.51 6 0.04 nmol/mg control value,
mean 6 SEM; n ¼ 3; P < 0.05). It can be concluded that the
remarkable suppression of microsomal cortisol production
observed in intact microsomes (Fig. 1) cannot be attributed to
direct inhibition of either protein component involved in the
process.
3.3. Luminal Redox Shift in EGCG-Treated Microsomes
The above results show that intact membrane barrier and
retained compartmentation are prerequisites for an efficient
inhibition of the cortisol producing machinery by EGCG. This
strongly suggests that the existence of a separate NADPþ-
NADPH pool plays a key role in the mechanism of action, and
oxidation of luminal NADPH might underlie the attenuation of
cortisone reduction, as it was reported earlier in case of
metyrapone [5].
Alteration in the redox state of luminal NADPþ-NADPH
pool was first studied by estimating the endogenous reducing-
oxidizing capacity of the microsomes, that is, their intrinsic
ability to convert cortisone to cortisol and vice versa. The rele-
vant enzyme activities were essentially not affected by EGCG;
therefore, they could be reliably utilized in such an indirect
analysis. Intact microsomes were incubated with either corti-
sone or cortisol and the rate of cortisol or cortisone production
(driven merely by endogenous reducing or oxidizing power)
was measured by HPLC. Cortisone reducing power of the mi-
crosomes (control activity: 0.55 6 0.04 pmol/min/mg protein;
mean 6 SEM; n ¼ 3) was remarkably suppressed by EGCG in
a concentration-dependent manner (Fig. F55). The effect was al-
ready significant at 25 lM level, and cortisol production was
not detectable in the presence of the flavanol at 50 lM concen-
tration or above. At the same time, cortisol oxidation (control
activity: 2.37 6 0.31 pmol/min/mg protein; mean 6 SEM; n ¼
3) was largely enhanced by EGCG treatment (Fig. 5). The effect
was saturable: the rate of cortisone production could be more
than doubled upon addition of 50 lM EGCG and did not further
increase at higher concentrations of the flavanol.
Shift in the endogenous cortisol–cortisone conversion to-
ward cortisone production is likely due to oxidation of luminal
pyridine nucleotides. Therefore, changes in NADPH content of
the ER vesicles were also assessed directly by fluorimetry.
Luminal NADPH can be detected as stable baseline fluores-
cence in intact microsomal vesicles. Addition of EGCG caused
a remarkable decrement of this signal, which could be par-
tially reverted by the addition of G6P (Fig. F66). This phenom-
enon corresponds to an EGCG-induced conversion of luminal
NADPH to NADPþ and a concomitant G6P-driven regeneration
of NADPH. Similar redox shift was detected upon the addition
of metyrapone (Fig. 6) or cortisone (not shown) in accordance
with several studies reported earlier [9,29]. When NADPH was
added to a protein free EGCG solution (100 lM) in the same
NADPþ-driven cortisol oxidation in permeabilized mi-
crosomes. 11bHSD1 activity was assessed separately
on the basis of cortisol–cortisone conversion. Micro-
somes (0.5 mg/mL protein) permeabilized with ala-
methicin (0.1 mg/mg protein) were incubated at 37
C for 30 min in MOPS-KCl buffer supplemented with
cortisol (5 lM) and NADPþ (50 lM) and EGCG in dif-
ferent concentrations as indicated. The amount of
cortisone was then measured with HPLC. The rate of
cortisone production was calculated and shown as
mean þ SEM, n ¼ 3, *P < 0.05 versus control.
Endogenous reducing and oxidizing capacities of the
liver microsomes. Intrinsic cortisone reducing or cor-
tisol oxidizing capacity of the microsomes was ana-
lyzed by incubating intact microsomal vesicles (0.5
mg/mL protein concentration) in MOPS-KCl buffer at
37 C for 2 h in the presence of 10 lM cortisone or
cortisol, respectively. The amounts of cortisol and
cortisone were then measured with HPLC. Data are
expressed as % of the control values (cortisone
reduction: 0.55 6 0.04 pmol/min/mg protein; cortisol
oxidation: 2.37 6 0.31 pmol/min/mg protein) and
shown as mean þ SEM, n ¼ 3, *P < 0.05, **P < 0.01
versus control. ND: not detectable (below 1% of
control).
FIG 4
FIG 5
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experimental condition, a sustained increase of the fluorescent
signal was recorded (not shown), which rules out both nonen-
zymatic oxidation of NADPH and fluorescence quenching by
EGCG.
The observed oxidative shift in the luminal NADPþ-NADPH
pool could be just part of a general oxidative stress involving
peroxidation. Therefore, the possible effect of EGCG on lipid
peroxidation was also tested and compared to ascorbate/Fe2þ
combination by measuring the amount of TBARS in rat liver
microsomes. According to the basically antioxidant features of
tea flavanols, EGCG slightly (although not significantly)
decreased rather than increased peroxidation of membrane
lipids (Fig. F77), which strongly contradicts the role of a massive
oxidative challenge in our system.
4. Discussion
Obesity epidemic is a global and growing medical problem.
The condition is often associated with a complex metabolic
disorder called the metabolic syndrome, which can lead to
type 2 diabetes. Many of the features of the common metabolic
syndrome resemble those of the rare Cushing zczc syndrome,
which indicates the role of glucocorticoid action despite nor-
mal plasma cortisol levels [10]. This finding drew attention to
the prereceptor mechanisms modulating the hormone actions.
Cortisol and the prohormone cortisone can be intercon-
verted by 11b-hydroxysteroid dehydrogenase types 1 and 2
(11bHSD1 and 2) in the target cells. These two isoenzymes are
fundamentally different regarding tissue specificity, topology,
cofactor dependence, and physiological function. The cytosolic
NADþ dependent 11bHSD2 is expressed in mineralocorticoid
target tissues, such as kidney, colon, and salivary glands. It
oxidizes cortisol to cortisone and thereby confers aldosterone
selectivity on inherently nonselective mineralocorticoid recep-
tors [30]. In contrast, the NADPH dependent 11bHSD1 is local-
ized in the ER and is expressed in the glucocorticoid target tis-
sues including liver, adipose tissue, and skeletal muscle, which
play key roles in the distribution, breakdown and storage of
fuel molecules in the human body. 11bHSD1 is capable of
Modulation of NADPH level in the microsomal
lumen. Endogenous NADPH content of intact micro-
somal vesicles was monitored at 1 mg/mL protein
concentration in MOPS-KCl buffer by detecting fluo-
rescence at 350-nm excitation and 500-nm emission
wavelengths. Oxidation of the luminal pyridine nucle-
otide pool was found after addition of 100 lM EGCG
(top panel) or 5 lM metyrapone (bottom panel). The
redox shift could be, at least partly, counteracted by
the administration of 100 lM G6P in both cases. Typ-
ical traces of three independent experiments are
shown.
Lipid peroxidation in the microsomes. Microsomal
vesicles (1 mg protein/mL) were incubated in MOPS-
KCl buffer for 5 min at 37 C, in the absence or pres-
ence of EGCG (50 or 100 lM). Lipid peroxidation
caused by the combination of 100 lM Fe2þ and 1
mM ascorbate was used as a positive control. Thio-
barbituric acid reactive substances (TBARS) were
detected in samples prepared by the addition of tri-
chloroacetic acid (5% final concentration). TBARS
contents of the microsomes did not change signifi-
cantly upon EGCG treatment. Data are shown as
mean þ SEM, n ¼ 3, **P < 0.01 versus control.
FIG 6
FIG 7
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reducing cortisone to cortisol, which makes this enzyme a
major modulating factor of the glucocorticoid action in the tar-
get cells [6], and also a key player in adipocyte differentiation
[5].
Mounting evidence support the role of local cortisol pro-
duction in the metabolic syndrome. All or most symptoms
appear in mice overexpressing 11bHSD1 [12,13], while
11bHSD1 knockout mice [16,17] seem to be protected from the
disease. Selective inhibitors of 11bHSD1 are, therefore, consid-
ered as promising novel agents for the treatment of metabolic
syndrome and diabetes [18]. However, reductase and dehydro-
genase activities of 11bHSD1 vary in different tissues [6]. Some
studies indicate cortisol oxidation by 11bHSD1 in subcutaneous
adipose tissue, and this seems to contribute to a recycling
between cortisol and cortisone in various human tissues in
vivo [31]. Inhibition of both reductase and dehydrogenase
activities of 11bHSD1 provides a limited effectiveness in
decreasing the overall glucocorticoid activity, which might
explain their limited success in phase 2 clinical trials. The se-
lectivity of such drug molecules should not only be focused on
the difference between 11bHSD1 and 2. The best therapeutic
efficacy could be expected from chemicals that specifically in-
hibit reductase activity of 11bHSD1 and, ideally, also increase
its dehydrogenase activity [18].
Localization of 11bHSD1 in a separate metabolic compart-
ment of the cell provides a special strategy to modulate the
balance between its dehydrogenase and reductase activities.
The ER luminal 11bHSD1 utilizes the separate NADPH-NADPþ
pool of the organelle. Whether the enzyme acts as a reductase
or dehydrogenase depends on the luminal redox conditions
(i.e., NADPH:NADPþ ratio), which underlines the importance of
compartmentation [7]. Reductase activity dominates in the
liver, which is considered as the major source of extra-adrenal
cortisol production [32]. Cortisone reducing capacity of hepatic
microsomes has been shown to decrease progressively during
starvation in rats [29], which strongly supports the theory that
the luminal redox conditions play a central role in the nutrient
sensor function of the ER [33]. In addition, NADPH generation
and consequent cortisone reduction in the hepatic ER have
been recently shown to be fuelled by fructose 6-phosphate,
and this provides new perspective into the mechanism of how
fructose ingestion contributes to obesity and the metabolic syn-
drome [34]. Lack of 11bHSD1 reductase activity and increased
dehydrogenase activity was found in H6PD knockout mice,
which have starving hypoglycemia, increased insulin sensitivity
and are resistant to diabetogenic diet [14,15]. These observa-
tions indicate that chemicals capable of lowering the
NADPH:NADPþ ratio in the ER lumen of certain cells, particu-
larly in the liver, should be considered as promising antiobe-
sity and antidiabetic agents.
Oxidative shift in the ER luminal NADPH-NADPþ pool can
be achieved by the administration of metyrapone, as it has
been already demonstrated in several studies (e.g., 9, 5). How-
ever, metyrapone is primarily a steroid 11b-hydroxylase inhib-
itor and also a substrate of 11bHSD1, which nonselectively
inhibits both types of 11bHSD [35]; therefore, it cannot be
regarded as a promising drug molecule in the metabolic syn-
drome. Our results revealed that EGCG, the most abundant tea
flavanol causes the desirable redox shift in hepatic ER vesicles.
Efficient inhibition of cortisone reduction was found only in
intact microsomes. Our search for the underlying mechanism
revealed a pronounced oxidation of luminal NADPH to NADPþ,
which explains the observed dependence on membrane integ-
rity. EGCG treatment on its own did not damage the investi-
gated enzymes and membrane lipids, that is, 11bHSD1 and
H6PD activities were essentially unaffected and lipid peroxida-
tion was not enhanced, which indicates that NADPH oxidation
is not due to ROS generation in our experiments. Nonenzy-
matic direct interaction between EGCG and NADPH was also
ruled out. Considering the small volume of the ER (and ER-
derived vesicles), the phenomenon is likely attributable to an
NADPH consuming luminal enzyme of low capacity, which
remains to be identified.
The NADPH-NADPþ redox shift caused by EGCG in the ER
lumen might significantly contribute to the beneficial health
effects of tea flavanols. Moreover, the mean by which EGCG
interferes with microsomal cortisol generation highlights the
importance of the separate ER luminal pyridine nucleotide
pool as a potential drug target. This mechanism should be
regarded as a promising strategy for the development of novel
11bHSD1 inhibitors of double selectivity as it only affects the
ER luminal isoenzyme and definitely shifts cortisone–cortisol
conversion toward oxidation, which is desirable for the pre-
vention and treatment of obesity, metabolic syndrome, and
diabetes.
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